Scandion Oncology, today announced that a member of the Board of Directors has sold shares in the company to its fully owned holding company.
Board member Thomas Feldthus has sold a total of 28,182 shares to his fully owned holding company, Fertilizer Invest ApS, which is considered a closely associated person of Thomas Feldthus,
Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them.
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
E-mail: ir@scandiononcology.com
The information was provided by the contact person above for publication on January 19, 2022, at 17.30 CET.
Scandion Oncology, the Cancer Drug Resistance Company, is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.